Reckitt buys Paras for $726 million

As the year draws to a close, private-equity firm Actis orchestrates the sale of its portfolio company Paras Pharmaceuticals in India to Reckitt Benckiser for $726 million.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES